scholarly article | Q13442814 |
P356 | DOI | 10.1086/381202 |
P698 | PubMed publication ID | 14765345 |
P50 | author | Benjamin P. Howden | Q37837894 |
Tony M. Korman | Q40454333 | ||
James C. Hurley | Q56126227 | ||
P2093 | author name string | Kerry Read | |
M Lindsay Grayson | |||
Paul D R Johnson | |||
Elizabeth A Grabsch | |||
Barrie C Mayall | |||
Patrick G P Charles | |||
Philipp du Cros | |||
Arthur J Morris | |||
Jenny Robson | |||
Sally A Roberts | |||
Andrew Fuller | |||
Narin Bak | |||
Peter B Ward | |||
P2860 | cites work | Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know | Q31704853 |
Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis | Q33898620 | ||
Vancomycin resistance in staphylococci | Q33906522 | ||
Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia | Q34396414 | ||
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing th | Q34974539 | ||
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 | ||
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital | Q43552304 | ||
The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model | Q43778977 | ||
Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. | Q44302673 | ||
Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization | Q44340945 | ||
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin | Q45199316 | ||
Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. | Q54095666 | ||
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Staphylococcus aureus | Q188121 |
vancomycin | Q424027 | ||
methicillin-resistant Staphylococcus aureus | Q595158 | ||
P304 | page(s) | 521-528 | |
P577 | publication date | 2004-01-29 | |
P1433 | published in | Clinical Infectious Diseases | Q5133764 |
P1476 | title | Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | |
P478 | volume | 38 |
Q43621611 | A complicated prosthetic valve endocarditis due to methicillin resistant Staphylococci treated with linezolid and ciprofloxacin: a case report |
Q30455758 | A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin |
Q37277083 | Acquired vancomycin resistance in clinically relevant pathogens |
Q42071192 | Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014. |
Q41999444 | Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations |
Q36744836 | Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus |
Q38566653 | An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case report |
Q46708063 | Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011. |
Q41832910 | Antibiofilm and membrane-damaging potential of cuprous oxide nanoparticles against Staphylococcus aureus with reduced susceptibility to vancomycin |
Q36338182 | Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection |
Q36283731 | Antibiotic resistance in Staphylococcus aureus and its relevance in therapy |
Q36325685 | Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci |
Q37453459 | Assessment of therapeutic drug monitoring of vancomycin in elderly patients according to new guidelines |
Q35607636 | Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. |
Q53883692 | Bacterial and Lyme Arthritis. |
Q54447533 | Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. |
Q28534516 | Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis |
Q37238371 | Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy |
Q36898180 | Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). |
Q37124131 | Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection |
Q35066896 | Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au |
Q38425879 | Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus |
Q37849391 | Clinical management of Staphylococcus aureus bacteraemia |
Q38099554 | Clinical management of septic arthritis |
Q34157657 | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |
Q36083208 | Clinical update on linezolid in the treatment of Gram-positive bacterial infections |
Q41869403 | Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. |
Q50080441 | Comment: Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin |
Q36070903 | Community-associated methicillin-resistant Staphylococcus aureus: a review |
Q37153976 | Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy |
Q36171683 | Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model |
Q42718716 | Comparison of In-vitro Activities of Linezolid and Vancomycin against Staphylococcus aureus Isolated from A Tertiary Care Hospital |
Q37949553 | Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. |
Q41570947 | Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus |
Q35172374 | Convergent adaptation in the dominant global hospital clone ST239 of methicillin-resistant Staphylococcus aureus. |
Q42855424 | Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies |
Q35026521 | Current and novel antibiotics against resistant Gram-positive bacteria |
Q37722741 | Current diagnostic tools for methicillin-resistant Staphylococcus aureus infections. |
Q35771368 | Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus |
Q44279637 | Daptomycin in complicated skin and soft tissue infections |
Q36744825 | Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus |
Q24620644 | Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole |
Q45121503 | Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin |
Q36969754 | Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression |
Q41915895 | Development and stability studies of novel liposomal vancomycin formulations. |
Q61757070 | Diagnose und Therapie der Sepsis |
Q44754456 | Diagnosis and therapy of sepsis |
Q33321447 | Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia |
Q46987530 | Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia |
Q34481625 | Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus |
Q58762088 | Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus |
Q36584656 | Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat |
Q40758601 | Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin |
Q26823518 | European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid |
Q49874675 | Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates |
Q42445383 | Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations |
Q41907664 | Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro |
Q34058222 | Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus |
Q41429045 | Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods |
Q28477900 | Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR |
Q41016957 | First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia |
Q36439147 | Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus |
Q34161745 | General principles of antimicrobial therapy |
Q36932920 | Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus |
Q38545589 | Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. |
Q24542412 | Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients |
Q36452459 | Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin |
Q37717901 | Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance |
Q36692468 | Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance |
Q33369409 | High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease |
Q35123536 | High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis |
Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
Q98205022 | Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus |
Q42111799 | Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model |
Q37263399 | Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia. |
Q36287998 | Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. |
Q35934534 | Importance of Decision Support Implementation in Emergency Department Vancomycin Dosing. |
Q42653995 | Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility? |
Q42738202 | In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates |
Q42130598 | In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types |
Q37263546 | In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus |
Q40326741 | In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus |
Q59811853 | Incidence and risk factors for potentially suboptimal serum concentrations of vancomycin during cardiac surgery |
Q41066970 | Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period |
Q37156698 | Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains |
Q36416898 | Infective endocarditis treated with linezolid: case report and literature review. |
Q46826194 | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia |
Q38019608 | Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs |
Q35096913 | Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics |
Q35023343 | Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia |
Q38995472 | Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults |
Q34894133 | Linezolid for the treatment of drug-resistant infections |
Q37600404 | Linezolid: a review of safety and tolerability |
Q40327481 | Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans |
Q36025384 | Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. |
Q37947249 | MRSA: the first half century |
Q30234954 | Management and Novel Adjuncts of Necrotizing Soft Tissue Infections. |
Q37700552 | Management of antibiotic resistance in the intensive care unit setting |
Q36322109 | Management of healthcare-associated methicillin-resistant Staphylococcus aureus |
Q37156709 | Management of methicillin-resistant Staphylococcus aureus bacteremia |
Q34657311 | Mechanisms of antibiotic resistance in Staphylococcus aureus |
Q80585586 | Medical treatment of endocarditis |
Q54210717 | Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality. |
Q35026548 | Methicillin-resistant Staphylococcus aureus in HIV-infected patients |
Q36939685 | Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. |
Q42272352 | Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation |
Q36328966 | Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains |
Q34489407 | Mitigation of Staphylococcus aureus-mediated surgical site infections with ir photoactivated TiO2 coatings on Ti implants. |
Q33500363 | Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients |
Q33776656 | Necrosis of Staphylococcus aureus by the Electrospun Fe- and Ag-Doped TiO2 Nanofibers |
Q43438833 | Necrotizing soft tissue infections in the intensive care unit |
Q36953330 | New antimicrobial agents as therapy for resistant gram-positive cocci |
Q37860558 | New trends in infective endocarditis |
Q41873909 | Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus |
Q36903680 | Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus |
Q42943425 | Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus |
Q90701768 | Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens |
Q36777850 | Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections |
Q42664007 | Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis |
Q47634145 | Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia. |
Q38066654 | Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia |
Q34529205 | Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. |
Q33683520 | Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model |
Q33826193 | Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus |
Q36644689 | Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter? |
Q33602468 | Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience |
Q35940556 | Predictors of mortality in Staphylococcus aureus Bacteremia |
Q36636699 | Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients |
Q40085144 | Prevalence of Slow-growth Vancomycin Non-susceptibility In Methicillin-resistant Staphylococcus aureus |
Q33974292 | Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine |
Q37274726 | Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. |
Q61757039 | Prävention, Diagnose, Therapie und Nachsorge der Sepsis |
Q34022843 | Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS. |
Q64131294 | Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico |
Q37114426 | Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection |
Q24646677 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications |
Q38780029 | Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia |
Q27011138 | Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections |
Q35619094 | Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era |
Q64131298 | Resumen de las recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos gram positivos en el paciente crítico |
Q35038242 | Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure |
Q37672039 | Rifampin combination therapy for nonmycobacterial infections |
Q41479166 | Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection |
Q36153912 | Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus |
Q37860553 | Severe, non-bacteremic infections in ICU patients. |
Q58694105 | Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC |
Q46800394 | Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid |
Q37602845 | Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions |
Q28481497 | Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model |
Q37809666 | Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates |
Q35905561 | Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). |
Q37117865 | Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections |
Q36787486 | The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus |
Q34091829 | The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. |
Q22065665 | The importance of the development of antibiotic resistance in Staphylococcus aureus |
Q36328971 | The pharmacokinetic and pharmacodynamic properties of vancomycin |
Q38084726 | The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults |
Q37776832 | The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains |
Q36779557 | The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus |
Q34494676 | Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients |
Q34910366 | Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists |
Q42743427 | Tolerance and heteroresistance in Gram-positive microorganisms |
Q34630593 | Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing |
Q37478888 | Transplacental transfer of vancomycin and telavancin |
Q42914487 | Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria |
Q36758570 | Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions |
Q37681564 | Treatment strategies for infective endocarditis. |
Q37322249 | Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics |
Q34402839 | Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus |
Q33909407 | USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit |
Q37203845 | Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia |
Q54392892 | Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? |
Q43117809 | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years |
Q95355781 | Vancomycin Resistance in Staphylococcus aureus |
Q42779344 | Vancomycin dosing in patients undergoing maintenance hemodialysis. |
Q38462842 | Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice |
Q34405301 | Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis |
Q37340562 | Vancomycin resistance: are there better glycopeptides coming? |
Q37236231 | Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system |
Q42153532 | Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates |
Q38062923 | Vancomycin therapeutics and monitoring: a contemporary approach. |
Q40483972 | Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer |
Q43094503 | Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041. |
Q34585059 | Vascular catheter-associated infections: a microbiological and therapeutic update. |
Q38632488 | When sepsis persists: a review of MRSA bacteraemia salvage therapy |
Q42197385 | daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations |
Q33624615 | pH-Dependent Antimicrobial Properties of Copper Oxide Nanoparticles in Staphylococcus aureus |
Search more.